Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
– Expansion cohorts to include patients with advanced kidney, prostate and bladder cancers –
ALAMEDA